Annual report [Section 13 and 15(d), not S-K Item 405]

Geographic and segmental information - Major Customers (Details)

v3.25.1
Geographic and segmental information - Major Customers (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Segment reporting      
Total operating expenses $ (246,792) $ (200,022) $ (191,113)
Loss from operations (68,760) (139,741) (163,965)
Interest income 6,596 5,964 1,542
Interest expense (3,348)    
Gain on bargain purchase   22,049  
Other income (expense), net (1,726) (807) (536)
Income tax expense (3,576) (1,336) (2,497)
Net loss attributable to ordinary shareholders (70,814) (113,871) (165,456)
Single reportable segment      
Segment reporting      
Revenue 178,032 60,281 27,148
Research (13,404) (13,228) (22,912)
CMC and Quality (61,350) (60,466) (61,850)
Biomarkers (8,227) (4,235) (8,977)
Development and Compliance (52,737) (43,863) (43,614)
Infrastructure management and Facilities (31,739) (28,481) (25,266)
Commercial and Commercial planning (15,860) (3,344) (4,329)
Support and corporate functions (45,186) (43,614) (32,483)
Other segment expenses $ (18,289) $ (2,791) $ 8,318
Other segment expenses description (a)Other segment expenses includes reimbursements receivable for research and development tax and expenditure credits, depreciation, amortization, impairment of long-lived assets and share-based compensation expenses which are included in Note 2q, Note 6, Note 7, Note 17 and Note 12, respectively. Restructuring charges are included in Support and corporate functions and disclosed in Note 17. (a)Other segment expenses includes reimbursements receivable for research and development tax and expenditure credits, depreciation, amortization, impairment of long-lived assets and share-based compensation expenses which are included in Note 2q, Note 6, Note 7, Note 17 and Note 12, respectively. Restructuring charges are included in Support and corporate functions and disclosed in Note 17. (a)Other segment expenses includes reimbursements receivable for research and development tax and expenditure credits, depreciation, amortization, impairment of long-lived assets and share-based compensation expenses which are included in Note 2q, Note 6, Note 7, Note 17 and Note 12, respectively. Restructuring charges are included in Support and corporate functions and disclosed in Note 17.
Total operating expenses $ (246,792) $ (200,022) $ (191,113)
Loss from operations (68,760) (139,741) (163,965)
Interest income 6,596 5,964 1,542
Interest expense (3,348)    
Gain on bargain purchase   22,049  
Other income (expense), net (1,726) (807) (536)
Income tax expense (3,576) (1,336) (2,497)
Net loss attributable to ordinary shareholders $ (70,814) $ (113,871) $ (165,456)